drugset / Trial / NCT00584974

A Safety, Efficacy and Tolerability Study of SEP-225289

NCT00584974

Phase 2 Completed 523 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder

Timeline

Start
2007-12
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasotraline Small molecule 0.5 mg
Subject Dasotraline Small molecule 2 mg
Comparator Venlafaxine Small molecule 150 mg